Daykin Anne, Selman Lucy E, Cramer Helen, McCann Sharon, Shorter Gillian W, Sydes Matthew R, Gamble Carrol, Macefield Rhiannon, Lane J Athene, Shaw Alison
MRC ConDuCT Hub for Trials Methodology Research, School of Social and Community Medicine, University of Bristol, Bristol, BS8 2PS, UK.
Formerly: Health Services Research Unit, University of Aberdeen, Aberdeen, AB25 2ZD, UK.
Trials. 2016 Jul 1;17(1):307. doi: 10.1186/s13063-016-1425-y.
Clinical trials oversight by a Trial Steering Committee (TSC) is mandated by Good Clinical Practice. This study used qualitative methods to explore the role and valued attributes of the TSC to inform planned updates of Medical Research Council guidance and TSC terms of reference.
An ethnographic study was conducted during 2013-2014. TSC and Trial Management Group meetings from eight trials were observed and audio-recorded, and semi-structured interviews conducted with purposively sampled key informants: independent and non-independent TSC members, trial sponsor representatives, funder representatives and chief investigators. The selected trials were currently recruiting and dealing with challenging scenarios. Data were analysed thematically and findings triangulated and integrated to give a multi-perspective account of the role and valued attributes of a TSC.
Eight TSC meetings and six Trial Management Group meetings were observed. Sixty-five interviews were conducted with 51 informants. The two main roles played by the TSC were quality assurance and patient advocacy. Quality assurance involved being a 'critical friend' or a provider of 'tough love'. Factors influencing the ability of the TSC to fulfil this role included the TSC Chair, other independent TSC members and the model of the TSC and its fit with the trial subject. The role of the TSC as an advocate for patient well-being was perceived as paramount. Two attributes of TSC members emerged as critical: experience (of running a trial, trial oversight or in a clinical/methodological area) and independence. While independence was valued for giving impartiality, the lack of consensus about its definition and strict requirements of some funders made it difficult to operationalise.
We found tensions and ambiguities in the roles expected of TSCs and the attributes valued of TSC members. In particular, the requirements of independence and experience could conflict, impacting the TSCs' quality assurance role. Concerns were raised regarding whose interests are served by funders' criteria of independence; in particular, funders' selection of TSC members was thought to potentially inhibit TSCs' ability to fulfil their patient advocacy role. These findings should be incorporated in revising guidance and terms of reference for TSCs.
临床试验指导委员会(TSC)对临床试验的监督是《药物临床试验质量管理规范》所要求的。本研究采用定性方法,探讨TSC的作用和重要属性,以为医学研究理事会指南及TSC职权范围的计划更新提供参考。
于2013年至2014年开展了一项人种学研究。观察并录音了八项试验的TSC会议和试验管理小组会议,并对经过目的抽样的关键信息提供者进行了半结构式访谈:独立和非独立的TSC成员、试验申办方代表、资助方代表和首席研究员。所选试验当时正在招募受试者并应对具有挑战性的情况。对数据进行了主题分析,并对研究结果进行了三角互证和整合,以从多个角度说明TSC的作用和重要属性。
观察了八次TSC会议和六次试验管理小组会议。对51名信息提供者进行了65次访谈。TSC发挥的两个主要作用是质量保证和患者权益维护。质量保证包括充当“关键之友”或提供“严厉的爱”。影响TSC履行这一职责能力的因素包括TSC主席、其他独立TSC成员以及TSC的模式及其与试验主题的契合度。TSC作为患者福祉倡导者的作用被视为至关重要。TSC成员的两个属性显得至关重要:经验(进行试验、试验监督或在临床/方法学领域的经验)和独立性。虽然独立性因其能提供公正性而受到重视,但对于其定义缺乏共识以及一些资助方的严格要求使其难以实施。
我们发现TSC预期发挥的作用与TSC成员所看重的属性之间存在紧张关系和模糊之处。特别是,独立性和经验的要求可能相互冲突从而影响TSC的质量保证作用。对于资助方的独立性标准服务于谁的利益存在担忧;尤其是,资助方对TSC成员的挑选被认为可能会抑制TSC履行其患者权益维护职责的能力。这些研究结果应纳入TSC指南和职权范围的修订中。